ReviewInternational journal of molecular sciences2018
Non-Coding RNA in the Pathogenesis, Progression and Treatment of Hypertension.
Review in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 48 citations in OpenAlex.
- Association of miR-133a With Microalbuminuria in Patients With Resistant Arterial Hypertension and Chronic Kidney Disease.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
- Whole transcriptome analysis reveals differential gene expression associated with Anaplasma phagocytophilum invading HL-60 cells.Parasites & vectors · 2026Article
- MicroRNAs in Pediatric Primary Hypertension: Promising Biomarkers or Context-Dependent Regulators?-A Narrative Review.Biomolecules · 2026Review
- Review
- Role and relevance of exosome-mediated epigenetic regulation in the pathogenesis, diagnosis and treatment of cardiovascular diseases (Review).Molecular medicine reports · 2026Review
- The multifaceted roles of non-coding RNAs in cell-cell communication in cardiovascular health and disease.Cell & bioscience · 2025Review
- Screening and analysis of plasma differential lncRNA/mRNA in early pregnancy of preeclampsia.Malawi medical journal : the journal of Medical Association of Malawi · 2025Article
- Associations of microRNA Gene Polymorphisms With Salt Sensitivity, Longitudinal Blood Pressure Changes, and Hypertension Incidence in the Chinese Population.Journal of clinical hypertension (Greenwich, Conn.) · 2025Article
- Review
- Genetic and Epigenetic Mechanisms Regulating Blood Pressure and Kidney Dysfunction.Hypertension (Dallas, Tex. : 1979) · 2024Review
- Investigation of Antihypertensive Properties of Chios Mastic via Monitoring microRNA-21 Expression Levels in the Plasma of Well-Controlled Hypertensive Patients.Non-coding RNA · 2024Article
- Histone Modifications and Their Contributions to Hypertension.Hypertension (Dallas, Tex. : 1979) · 2024Review
- Analysis of miRNAs inPharmaceuticals (Basel, Switzerland) · 2023Article
- Article
- Article
- The Emerging Role of MicroRNAs in Bone Diseases and Their Therapeutic Potential.Molecules (Basel, Switzerland) · 2021Review
- Therapeutic advances of miRNAs: A preclinical and clinical update.Journal of advanced research · 2021Review
- MiRNAs, lncRNAs, and circular RNAs as mediators in hypertension-related vascular smooth muscle cell dysfunction.Hypertension research : official journal of the Japanese Society of Hypertension · 2021Review
- The Expression of miR-365 in Serum of Hypertension Patients with Left Ventricular Hypertrophy Was Up-Regulated, Which Was Positively Correlated with Left Ventricular Mass Index.Pharmacogenomics and personalized medicine · 2021Article
- The current state of MiRNAs as biomarkers and therapeutic tools.Clinical and experimental medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Hypertension is a complex, multifactorial disease that involves the coexistence of multiple risk factors, environmental factors and physiological systems. The complexities extend to the treatment and management of hypertension, which are still the pursuit of many researchers. In the last two decades, various genes have emerged as possible biomarkers and have become the target for investigations of specialized drug design based on its risk factors and the primary cause. Owing to the growing technology of microarrays and next-generation sequencing, the non-protein-coding RNAs (ncRNAs) have increasingly gained attention, and their status of redundancy has flipped to importance in normal cellular processes, as well as in disease progression. The ncRNA molecules make up a significant portion of the human genome, and their role in diseases continues to be uncovered. Specifically, the cellular role of these ncRNAs has played a part in the pathogenesis of hypertension and its progression to heart failure. This review explores the function of the ncRNAs, their types and biology, the current update of their association with hypertension pathology and the potential new therapeutic regime for hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.